This Viewpoint discusses whether the changes in the health care marketplace, the evolution of precision medicine, and the uniqueness of drug development and labeling for cancer diagnoses make the Orphan Drug Act less necessary and less relevant today than at its inception.
https://ift.tt/2MLeB2B
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
-
Publication date: June 2018 Source: Acta Biomaterialia, Volume 73 https://ift.tt/2kBbISt
-
http://bit.ly/2SylJiJ
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου